Abiraterone
- Generic Name
- Abiraterone
- Brand Names
- Yonsa, Zytiga, Abiraterone Krka, Abiraterone Accord, Abiraterone Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C24H31NO
- CAS Number
- 154229-19-3
- Unique Ingredient Identifier
- G819A456D0
- Background
Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis. Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resis...
- Indication
Abiraterone is indicated for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in combination with methylprednisolone or prednisone.
...
- Associated Conditions
- Metastatic Castration Sensitive Prostate Cancer (mCSPC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Associated Therapies
- -
Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-01-29
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Cardiff Oncology
- Target Recruit Count
- 72
- Registration Number
- NCT03414034
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-12-04
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT03360721
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate
- Conditions
- Interventions
- First Posted Date
- 2017-11-29
- Last Posted Date
- 2017-11-29
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT03356444
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
- First Posted Date
- 2017-09-29
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 28
- Registration Number
- NCT03298087
- Locations
- 🇺🇸
VA Long Beach Healthcare System, Long Beach, CA, Long Beach, California, United States
🇺🇸VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States
🇺🇸Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia, United States
Optimal Sequencing of Treatment Options for Poor Risk mCRPC Previously Treated With Docetaxel
- Conditions
- Interventions
- First Posted Date
- 2017-09-28
- Last Posted Date
- 2022-04-15
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 100
- Registration Number
- NCT03295565
- Locations
- 🇳🇱
Deventer Ziekenhuis, Deventer, Netherlands
🇳🇱Academisch medisch centrum Maastricht, Maastricht, Netherlands
🇳🇱Haga Ziekenhuis, The Hague, Netherlands
Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 86
- Registration Number
- NCT03279250
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Efficacy of Rotations Between Abiraterone Acetate and Apalutamide in mCRPC Patients
- Conditions
- Interventions
- First Posted Date
- 2017-06-02
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- University of Athens
- Registration Number
- NCT03173859
Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 73
- Registration Number
- NCT03150056
- Locations
- 🇬🇧
GSK Investigational Site, Glasgow, United Kingdom
Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma
- First Posted Date
- 2017-05-09
- Last Posted Date
- 2017-05-10
- Target Recruit Count
- 10
- Registration Number
- NCT03145285
- Locations
- 🇮🇹
U.O Oncologia Medica, Brescia, BS, Italy
Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
- Conditions
- Interventions
- First Posted Date
- 2017-05-05
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 345
- Registration Number
- NCT03141671
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Yale Cancer Center, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.